SPP Spring 2019 Meeting
March 15^th - 17th, 2019 
Crystal Gateway Marriott
(within driving distance of National Harbor, MD)

Quicklinks

Click here to make your hotel reservation

Committee Meetings – March 15^th, 2019
Scientific and Educational Sessions – March 16^th, 2019 and March 17^th, 2019 Symposium: “Lymph Node Pathology for the Pediatric Pathologist”

Andrea N. Marcogliese MD, Baylor College of Medicine
M. Kamran Mirza, MD PhD, Loyola University Medical Center, Aliya N. Husain, MD, University of Chicago, Kevin E. Fisher, MD, PhD, Texas Children’s Hospital, Carl Allen MD, PhD, Texas Children's Cancer Center 

Upon completion of this educational activity, participants will be able to:

• Identify the 2016 updates to pediatric lymphomas and lymphoproliferative disorders in the WHO classification of pediatric hematologic malignancies
• Use touch preparations and review fine needle aspirate smears to accurately assess lymphoid tissue and select appropriate testing to make a diagnosis and make best use of tissue, especially when limited, and utilize a comprehensive yet cost effective approach to the diagnosis of lymphoid lesions
• Integrate molecular diagnostic data into diagnostic algorithms and appropriately order and interpret test results in the context of a diagnostic work up of lymphoma and select appropriate ancillary studies that identify potential prognostic and/or therapeutic markers relevant to lymphomas
  
  Workshop Session I
  
  A. Year 1/3: Role of Bias in Pediatric Pathology: Preventing Errors and Enhancing Patient Safety One Child at a Time. Vinay Prasad, MD, Monroe Carrell Jr. Children's Hospital at Vanderbilt, Kathleen Nicol, MD, Nationwide Children's Hospital, The Ohio State University

At the end of this presentation, participants should be able to:

• Identify different cognitive biases that can cause errors
• Participants will be able to utilize de-biasing strategies, thereby preventing errors
• Participants will understand the dual processing system that we use every day, and utilize their understanding of Type 1 (intuitive) and Type 2 (analytic) processes to avoid errors and failure.

B. Year 2/3: Bone dysplasias: A systematic diagnostic approach - Linda Ernst, MD, Northshore University Healthsystem, Evanston Hospital and Peter Nikkels, MD, University Medical Center Utrecht, Netherlands         

At the end of this presentation, participants should be able to:

• Describe the diagnostic histological aspects of some common skeletal dysplasia’s recognizable at birth.
• Describe the diagnostic features of the X-rays of several common skeletal dysplasias recognizable at birth.
• Recognize the limitations of histology to diagnose a skeletal dysplasia.
• Use a diagnostic scheme to diagnose the more common skeletal dysplasia’s recognizable at birth.

C. Year 3/3: Pediatric Gastrointestinal Biopsy: An Update on the Diagnosis and Pathogenesis of Pediatric Upper Gastrointestinal Disease - Amy Lowichik, MD, PhD, University of Utah School of Medicine, Salt Lake City, UT and Raul S. Gonzalez, MD, University of Rochester Medical Center, Rochester, NY                                               

At the end of this presentation, participants should be able to:

• Recognize the inflammatory findings characteristic of allergic and autoimmune diseases of the pediatric upper gastrointestinal tract.
• Describe the histologic criteria for pre-malignant and malignant lesions of the pediatric upper gastrointestinal tract.
• Order and recommend appropriate ancillary testing for common and rare developmental, allergic, autoimmune, pre-malignant and malignant lesions of the pediatric upper gastrointestinal tract. 

Workshop Session II

D. Year 1/3: What Can the Placenta Tell Us? Debra S. Heller, MD, Rutgers-New Jersey Medical School, Rebecca N. Baergen, MD, Weill Cornell Medical College – New York Presbyterian Hospital

At the end of this presentation, participants should be able to:

• Diagnose placental lesions with a risk of recurrence in future pregnancies
• Diagnose placental lesions associated with neurologic injury and stillbirth
• Understand the terminology used in placental pathology including the Amsterdam Placental Workshop Guidelines
  
  E. Year 2/3: What every pediatric pathologist needs to know: WHO Classification of Tumors of the Central Nervous System (2016) Pediatric Tumors – Alexander Judkins, MD, Children's Hospital Los Angeles and Cynthia Hawkins, MD, Hospital for Sick Children, Toronto and Mariarita Santi, MD, Children's Hospital of Philadelphia             
  
  At the end of this presentation, participants should be able to:  
  Cynthia Hawkins:
  
• Apply the 2016 WHO Classification of Tumors of the Central Nervous System to the diagnosis of medulloblastoma
• Integrate morphologic and molecular results into a comprehensive pathology report for the diagnosis of medulloblastoma
• Apply immunohistochemical and molecular techniques to determine medulloblastoma molecular subgroup
• Appreciate the clinical relevance of molecular subgrouping and TP53 mutation status in medulloblastoma
  
  Alexander Judkins:
• Apply the 2016 WHO Classification of tumors of the Central Nervous System to the diagnosis of pediatric embryonal CNS tumors (non-medulloblastoma)
• Integrate morphologic and molecular results into a comprehensive pathology report for the diagnosis of pediatric embryonal CNS tumors (non-medulloblastoma).
• Distinguish AT/RT lacking histological features of rhabdoid differentiation from other pediatric CNS embryonal tumors on the basis of immunohistochemistry and/or molecular analysis of SMARCB1/INI1 and/or SMARCA4/BRG1.
• Using their molecular profile, distinguish C19MC-altered embryonal tumors from other pediatric embryonal CNS tumors.
  
  Mariarita Santi:
  
  
• Apply the 2016 WHO Classification of tumors of the Central Nervous System to the diagnosis of pediatric glial tumors
• Approach the diagnosis of pediatric glial brain tumors using a combination of morphology and molecular diagnostic techniques
• Distinguish the BRAF mutated glial tumors from the Histone-3 mutated tumors and extrapolate the prognostic implications.
• Separate the molecular profile of supratentorial ependymomas from the infratentorial
• Integrate morphologic and molecular results into a comprehensive pathology report.

F. Year 3/3: Challenges in Pediatric Soft Tissue Pathology: A Case-Based Approach to Selected Difficult Cases- Jennifer Black, MD, University of Colorado Anschutz School of Medicine, Children’s Hospital Colorado, Aurora, Colorado and Erin R. Rudzinski, MD; Seattle Children’s Hospital, Seattle, Washington                           

At the end of this presentation, participants should be able to:

• Describe the distinguishing features and the differential diagnosis for frequently encountered pediatric soft tissue lesions and their histologic mimics.
• Select appropriate ancillary tests to confirm diagnosis, including a strategic panel of immunohistochemical stains, electron microscopy, conventional cytogenetics analysis and molecular genetic testing.
• Create a pathology report including all essential information for the diagnosis of an intermediate or malignant soft tissue lesion to facilitate further patient management.

SAVE THE DATE

Combined SPP - PPS Meeting  
October 16-20, 2019
Pittsburgh, Pennsylvania

The Society for Pediatric Pathology is soliciting proposals for the 2020, 2021 and 2022 SPP Fall Meeting host institutions.

The Society holds a Fall Meeting each year at various pediatric institutions throughout North America; this Meeting includes the presentation of scientific abstracts, and a symposium that draws upon the expertise of local faculty, and a separate symposium on a perinatal topic. An informal atmosphere allows for interchange among colleagues and an opportunity to visit the institutions of peers.

If you are interested in submitting a proposal, please read the Host Responsibilities document and submit your proposal via email to Patricia Ferchland-Bingham. If you're planning to propose a meeting, please specify which on the proposal form.